Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for...

In a world first, ASX-listed medtech Imugene has dosed the first cancer patient with its novel onCARlytics CD19 virus technology which it...

Imugene is poised to secure further development opportunities for its “super-charged” cell immunotherapy programs after putting them on...

The United States Food and Drug Administration has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer...

Cancer fighter Imugene has positioned itself as one of the most cashed-up med-tech companies on the ASX after raising a further $18.2...

Clinical-stage immuno-oncology company Imugene has secured new Japan Patent Office protection for its “PD1-Vaxx” that is currently in the...

Cancer-fighter Imugene says it has received positive feedback from the United States Food and Drug Administration on its proposed trials...

Clinical stage cancer-fighting company Imugene has revealed that the phase-one trial of its anti-cancer virus “Vaxinia”, which is...

A worldwide license to attack blood cancer

Fresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is on a steadfast mission to activate...

Cancer drug trial green lit by US FDA